179 related articles for article (PubMed ID: 37826990)
1. Harnessing the druggability at orthosteric and allosteric sites of PD-1 for small molecule discovery by an integrated in silico pipeline.
Mittal L; Tonk RK; Awasthi A; Asthana S
Comput Biol Chem; 2023 Dec; 107():107965. PubMed ID: 37826990
[TBL] [Abstract][Full Text] [Related]
2. Targeting cryptic-orthosteric site of PD-L1 for inhibitor identification using structure-guided approach.
Mittal L; Tonk RK; Awasthi A; Asthana S
Arch Biochem Biophys; 2021 Nov; 713():109059. PubMed ID: 34673001
[TBL] [Abstract][Full Text] [Related]
3. Virtual screening of a natural compound library at orthosteric and allosteric binding sites of the neurotensin receptor.
Rejwan Ali M; Sadoqi M; Boutajangout A; Mezei M
J Biomol Struct Dyn; 2019 Oct; 37(17):4494-4506. PubMed ID: 30479178
[TBL] [Abstract][Full Text] [Related]
4. Molecular Modeling Study of a Receptor-Orthosteric Ligand-Allosteric Modulator Signaling Complex.
Jiang C; He X; Wang Y; Chen CJ; Othman Y; Hao Y; Yuan J; Xie XQ; Feng Z
ACS Chem Neurosci; 2023 Feb; 14(3):418-434. PubMed ID: 36692197
[TBL] [Abstract][Full Text] [Related]
5. Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist.
Pandey P; Roy KK; Doerksen RJ
J Biomol Struct Dyn; 2020 Jan; 38(1):32-47. PubMed ID: 30652534
[TBL] [Abstract][Full Text] [Related]
6. Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method.
Lim H; Chun J; Jin X; Kim J; Yoon J; No KT
Sci Rep; 2019 Nov; 9(1):16727. PubMed ID: 31723178
[TBL] [Abstract][Full Text] [Related]
7. Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors.
Lane JR; Chubukov P; Liu W; Canals M; Cherezov V; Abagyan R; Stevens RC; Katritch V
Mol Pharmacol; 2013 Dec; 84(6):794-807. PubMed ID: 24021214
[TBL] [Abstract][Full Text] [Related]
8. How Do Modulators Affect the Orthosteric and Allosteric Binding Pockets?
Chen CJ; Jiang C; Yuan J; Chen M; Cuyler J; Xie XQ; Feng Z
ACS Chem Neurosci; 2022 Apr; 13(7):959-977. PubMed ID: 35298129
[TBL] [Abstract][Full Text] [Related]
9. Computational discovery of small drug-like compounds as potential inhibitors of PD-1/PD-L1 interactions.
Urban VA; Davidovskii AI; Veresov VG
J Biomol Struct Dyn; 2023 Jul; 41(11):5345-5361. PubMed ID: 35696453
[TBL] [Abstract][Full Text] [Related]
10. Revealing the Positive Binding Cooperativity Mechanism between the Orthosteric and the Allosteric Antagonists of CCR2 by Metadynamics and Gaussian Accelerated Molecular Dynamics Simulations.
An X; Bai Q; Bing Z; Liu H; Zhang Q; Liu H; Yao X
ACS Chem Neurosci; 2020 Feb; 11(4):628-637. PubMed ID: 31968162
[TBL] [Abstract][Full Text] [Related]
11. PD-1-Targeted Discovery of Peptide Inhibitors by Virtual Screening, Molecular Dynamics Simulation, and Surface Plasmon Resonance.
Wang Y; Guo H; Feng Z; Wang S; Wang Y; He Q; Li G; Lin W; Xie XQ; Lin Z
Molecules; 2019 Oct; 24(20):. PubMed ID: 31640203
[TBL] [Abstract][Full Text] [Related]
12. Cross-talk between allosteric and orthosteric binding sites of γ-amino butyric acid type A receptors (GABA
Payghan PV; Nath Roy S; Bhattacharyya D; Ghoshal N
J Biomol Struct Dyn; 2019 Aug; 37(12):3065-3080. PubMed ID: 30608219
[TBL] [Abstract][Full Text] [Related]
13. Discovery of small-molecule PD-1/PD-L1 antagonists through combined virtual screening and experimental validation.
DiFrancesco M; Hofer J; Aradhya A; Rufinus J; Stoddart J; Finocchiaro S; Mani J; Tevis S; Visconti M; Walawender G; DiFlumeri J; Fattakhova E; Patil SP
Comput Biol Chem; 2023 Feb; 102():107804. PubMed ID: 36610303
[TBL] [Abstract][Full Text] [Related]
14. Druggable orthosteric and allosteric hot spots to target protein-protein interactions.
Ma B; Nussinov R
Curr Pharm Des; 2014; 20(8):1293-301. PubMed ID: 23713780
[TBL] [Abstract][Full Text] [Related]
15. Discovery of benzo[d]isothiazole derivatives as novel scaffold inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction through "ring fusion" strategy.
Gao Y; Wang H; Shen L; Xu H; Deng M; Cheng M; Wang J
Bioorg Chem; 2022 Jun; 123():105769. PubMed ID: 35405572
[TBL] [Abstract][Full Text] [Related]
16. Structure-based small inhibitors search combined with molecular dynamics driven energies for human programmed cell death-1 (PD-1) protein.
Waqas M; Halim SA; Alsalman A; Khan A; Elkord E; Al-Harrasi A
J Biomol Struct Dyn; 2023; 41(24):14771-14785. PubMed ID: 36927289
[TBL] [Abstract][Full Text] [Related]
17. Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective.
Shi D; Zhou S; Liu X; Zhao C; Liu H; Yao X
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):576-588. PubMed ID: 29203283
[TBL] [Abstract][Full Text] [Related]
18. Identification of the FDA-Approved Drug Pyrvinium as a Small-Molecule Inhibitor of the PD-1/PD-L1 Interaction.
Fattakhova E; Hofer J; DiFlumeri J; Cobb M; Dando T; Romisher Z; Wellington J; Oravic M; Radnoff M; Patil SP
ChemMedChem; 2021 Sep; 16(18):2769-2774. PubMed ID: 34117723
[TBL] [Abstract][Full Text] [Related]
19. Allosteric Modulators of Protein-Protein Interactions (PPIs).
Ni D; Liu N; Sheng C
Adv Exp Med Biol; 2019; 1163():313-334. PubMed ID: 31707709
[TBL] [Abstract][Full Text] [Related]
20. Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction.
Sasmal P; Kumar Babasahib S; Prashantha Kumar BR; Manjunathaiah Raghavendra N
Bioorg Med Chem; 2022 Nov; 73():117001. PubMed ID: 36126447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
